Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ABL-001 by Compass Therapeutics for Metastatic Biliary Tract Cancer: Likelihood of Approval
ABL-001 is under clinical development by Compass Therapeutics and currently in Phase III for Metastatic Biliary Tract Cancer. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Compass Pathways's ABL-001?
ABL-001 is a monoclonal antibody commercialized by Compass Pathways, with a leading Phase III program in Extrahepatic Bile Duct Cancer....